GSK, China’s Hengrui Pharma ink $500m deal to co-develop 12 innovative medicines
LONDON: GSK plc announced Monday that it has entered into agreements with China-based Hengrui Pharma to co-develop up to 12 innovative medicines spanning respiratory, immunology, inflammation and oncology indications, marking a major expansion of the British pharmaceutical giant’s pipeline beyond…